Key Takeaways
- • Lumira Ventures closed its fifth healthcare venture capital fund at first closing with a target size of US$200 million (C$275 million), representing the firm's seventh investment vehicle overall.
- • Fund V has already deployed capital, completing a US$52 million Series B financing for a pre-commercial-stage medical device company as its first investment.
- • Lumira's historical portfolio has generated substantial returns, with 25+ exits via IPOs and acquisitions, 40+ regulatory approvals, and over US$100 billion in cumulative revenue across portfolio companies touching 15+ million patients globally.
- • Since 2024, Lumira portfolio companies have achieved 7 exits at cumulative transaction values exceeding US$8 billion, raised over US$1.6 billion in follow-on capital, secured 7 new FDA approvals, and formed partnerships with 20+ strategic partners.
- • Leadership transition underway: co-founder Gerry Brunk elevated to Managing Partner, with Peter van der Velden transitioning to Executive Chairman as part of planned succession planning.
Summary
Lumira Ventures announced the first closing of Lumira Ventures V, LP on April 20, 2026, marking a significant milestone for the Toronto-based healthcare venture capital firm. The fund targets a final size of US$200 million (C$275 million) and has already deployed capital, completing a US$52 million Series B financing for a pre-commercial-stage medical device company. This closing represents the seventh investment fund established by Lumira and underscores the firm's continued focus on backing transformative biotechnology and medical technology companies across North America.
The firm is leveraging a demonstrated track record of portfolio success to drive investor confidence in Fund V. Over its multi-decade history, Lumira-backed companies have achieved 25+ exits through IPOs and strategic acquisitions and obtained 40+ regulatory approvals. More significantly, innovations developed by Lumira portfolio companies have reached 15+ million patients globally and generated over US$100 billion in cumulative revenue. Recent performance has been particularly strong: since 2024, Lumira portfolio companies have completed 7 exits valued at over US$8 billion in aggregate transaction value, raised more than US$1.6 billion in follow-on capital, and secured 7 new FDA product approvals while establishing relationships with 20+ strategic partners.
In conjunction with the Fund V closing, Lumira announced leadership changes reflecting its succession planning strategy. Co-founder Gerry Brunk has been named Managing Partner, positioning him to drive strategy and execution for Fund V and the firm's next phase of growth. Peter van der Velden has transitioned to the role of Executive Chairman, marking a planned evolution in the firm's leadership structure. The firm highlighted that Fund V will strengthen Lumira's Canadian leadership in healthcare venture investing while enabling an expanded focus on secondary North American ecosystems, broadening the geographic scope of deployment beyond primary markets.
The firm is leveraging a demonstrated track record of portfolio success to drive investor confidence in Fund V. Over its multi-decade history, Lumira-backed companies have achieved 25+ exits through IPOs and strategic acquisitions and obtained 40+ regulatory approvals. More significantly, innovations developed by Lumira portfolio companies have reached 15+ million patients globally and generated over US$100 billion in cumulative revenue. Recent performance has been particularly strong: since 2024, Lumira portfolio companies have completed 7 exits valued at over US$8 billion in aggregate transaction value, raised more than US$1.6 billion in follow-on capital, and secured 7 new FDA product approvals while establishing relationships with 20+ strategic partners.
In conjunction with the Fund V closing, Lumira announced leadership changes reflecting its succession planning strategy. Co-founder Gerry Brunk has been named Managing Partner, positioning him to drive strategy and execution for Fund V and the firm's next phase of growth. Peter van der Velden has transitioned to the role of Executive Chairman, marking a planned evolution in the firm's leadership structure. The firm highlighted that Fund V will strengthen Lumira's Canadian leadership in healthcare venture investing while enabling an expanded focus on secondary North American ecosystems, broadening the geographic scope of deployment beyond primary markets.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.